Harvard Apparatus Regenerative Technology Inc
OTC:HRGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Harvard Apparatus Regenerative Technology Inc
OTC:HRGN
|
US |
Harvard Apparatus Regenerative Technology Inc
Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2013-10-14. The company uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma or birth defects. Its Cellframe/Cellspan technology utilizes a biocompatible scaffold that is seeded with the patient’s own cells to create a Cellspan implant. Its product candidate includes Cellspan Esophageal Implant, Cellspan Bronchial Implants and Cellspan Tracheal Implants. The company is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection. Cellspan Tracheal Implants allow for the reconstruction of any portion of the trachea, potentially restoring its functional integrity. The company is also launching a consumer medicine division to promote advanced anti-aging technology and products in China.
Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2013-10-14. The company uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma or birth defects. Its Cellframe/Cellspan technology utilizes a biocompatible scaffold that is seeded with the patient’s own cells to create a Cellspan implant. Its product candidate includes Cellspan Esophageal Implant, Cellspan Bronchial Implants and Cellspan Tracheal Implants. The company is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection. Cellspan Tracheal Implants allow for the reconstruction of any portion of the trachea, potentially restoring its functional integrity. The company is also launching a consumer medicine division to promote advanced anti-aging technology and products in China.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
